8-K: TNF Pharmaceuticals Amends Terms of Series G Convertible Preferred Stock

TNF Pharmaceuticals has amended the terms of its Series G Convertible Preferred Stock regarding the calculation of in-kind dividend payments.

Summary

• TNF Pharmaceuticals amended the terms of its Series G Convertible Preferred Stock on August 8, 2024.
• The amendment modifies how the number of preferred shares issued for in-kind dividend payments is calculated.
• The change involves using the average closing price of the common stock over the five trading days before the dividend payment date, with a floor price.
• This amendment was made through an agreement with the Required Holders of the preferred stock.
• The Certificate of Amendment was filed with the Secretary of State of Delaware on August 8, 2024, and became effective immediately upon filing.

Sentiment

Score: 7

Explanation: The document reflects a necessary adjustment to the terms of the preferred stock, which is a neutral to slightly positive event. The agreement with the Required Holders is a positive sign of collaboration.

Positives

• The amendment provides clarity on how in-kind dividends will be calculated.
• The agreement with the Required Holders suggests a collaborative approach to managing the preferred stock terms.

Risks

• The change in dividend calculation could impact the value of the preferred stock.
• The reliance on the common stock price for in-kind dividends introduces volatility risk.

Management Comments

• The Board has duly adopted resolutions proposing to adopt this Amendment and declaring this Amendment to be advisable and in the best interest of the Company and its stockholders.

Industry Context

This type of amendment to preferred stock terms is not uncommon, especially when companies need to adjust their capital structure or dividend policies. It is important for investors to understand the implications of such changes.

Comparison to Industry Standards

• Many companies use preferred stock to raise capital, and the terms can vary widely.
• The use of a five-day average closing price for in-kind dividends is a specific mechanism that may not be standard across all companies.
• Companies like Amgen, Gilead, and Regeneron also use preferred stock, but their specific terms and conditions may differ significantly.

Stakeholder Impact

• Shareholders of the preferred stock will be directly impacted by the change in dividend calculation.
• Common stock shareholders may see indirect effects due to the potential impact on the company's capital structure.

Key Dates

Keywords

Series G Convertible Preferred Stock, Amendment, Dividends, In-Kind Payment, Preferred Stock, Securities Purchase Agreement, TNF Pharmaceuticals